Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11079357 | 0.78 | MEN1 (0.40) | PKMSMN1; SMN2 | |
| SCHEMBL24152289 | 0.78 | PKM (0.32) | PKMSMN1; SMN2 | |
| SCHEMBL12958892 | 0.76 | — | — | |
| SCHEMBL19419465 | 0.75 | — | — | |
| SCHEMBL28944683 | 0.75 | TRPM8 (0.39) | TRPM8RAB9A | |
| SCHEMBL25755688 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2TRPM8 | |
| SCHEMBL21952207 | 0.73 | — | — | |
| SCHEMBL14866812 | 0.72 | ALDH1A1 (0.40) | TRPM8RAB9A | |
| SCHEMBL14867051 | 0.71 | HSD17B10 (0.55) | RAB9A | |
| SCHEMBL7292726 | 0.71 | RAB9A (0.36) | SMN1; SMN2TRPM8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD (AU) | 2020-05-12 | — | — | US | disclosed |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2020-02-04 | — | — | US | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | PRMT5, PRMT1, PRMT3 | PKM 2031/4885SMN1; SMN2 3610/4885TRPM8 3861/4885 |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | PKM 1992/4885SMN1; SMN2 3457/4885TRPM8 3910/4885 |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | PRMT5, PRMT3, PRMT1 | PKM 1250/4885SMN1; SMN2 2617/4885TRPM8 4438/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | PKM 1318/4885SMN1; SMN2 2876/4885TRPM8 4449/4885 |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PKM 1381/4885SMN1; SMN2 3189/4885TRPM8 3832/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PKM 1381/4885SMN1; SMN2 3189/4885TRPM8 3832/4885 |
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PKM 2477/4885SMN1; SMN2 1531/4885TRPM8 4736/4885 |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PKM 2593/4885SMN1; SMN2 1659/4885TRPM8 4538/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | PKM 1250/4885SMN1; SMN2 2617/4885TRPM8 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.